News articles about Impax Laboratories (NASDAQ:IPXL) have trended somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Impax Laboratories earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 43.4189030940397 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
IPXL has been the topic of several research analyst reports. Royal Bank of Canada set a $20.00 price target on Impax Laboratories and gave the company a “hold” rating in a research report on Friday, March 2nd. Zacks Investment Research downgraded Impax Laboratories from a “hold” rating to a “sell” rating in a research report on Monday, March 12th. BidaskClub downgraded Impax Laboratories from a “hold” rating to a “sell” rating in a research report on Tuesday, March 6th. BMO Capital Markets raised their price target on Impax Laboratories from $18.00 to $20.00 and gave the company a “market perform” rating in a research report on Monday, April 16th. Finally, SunTrust Banks initiated coverage on Impax Laboratories in a research report on Wednesday, March 7th. They issued a “buy” rating and a $24.00 price target on the stock. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $22.12.
Get Impax Laboratories alerts:
IPXL stock opened at $18.30 on Friday. Impax Laboratories has a twelve month low of $13.05 and a twelve month high of $25.70. The stock has a market cap of $1.35 billion, a P/E ratio of 29.05, a PEG ratio of 0.83 and a beta of 1.15. The company has a debt-to-equity ratio of 4.11, a quick ratio of 1.52 and a current ratio of 1.96.
Impax Laboratories Company Profile
Impax Laboratories, Inc, a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.